210 related articles for article (PubMed ID: 31277465)
1. EDB-FN Targeted Peptide-Drug Conjugates for Use against Prostate Cancer.
Park SE; Shamloo K; Kristedja TA; Darwish S; Bisoffi M; Parang K; Tiwari RK
Int J Mol Sci; 2019 Jul; 20(13):. PubMed ID: 31277465
[TBL] [Abstract][Full Text] [Related]
2. EDB Fibronectin Specific Peptide for Prostate Cancer Targeting.
Han Z; Zhou Z; Shi X; Wang J; Wu X; Sun D; Chen Y; Zhu H; Magi-Galluzzi C; Lu ZR
Bioconjug Chem; 2015 May; 26(5):830-8. PubMed ID: 25848940
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and Assessment of Peptide Gd-DOTA Conjugates Targeting Extradomain B Fibronectin for Magnetic Resonance Molecular Imaging of Prostate Cancer.
Li Y; Han Z; Roelle S; DeSanto A; Sabatelle R; Schur R; Lu ZR
Mol Pharm; 2017 Nov; 14(11):3906-3915. PubMed ID: 28976766
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and antiproliferative activities of doxorubicin thiol conjugates and doxorubicin-SS-cyclic peptide.
Darwish S; Sadeghiani N; Fong S; Mozaffari S; Hamidi P; Withana T; Yang S; Tiwari RK; Parang K
Eur J Med Chem; 2019 Jan; 161():594-606. PubMed ID: 30396106
[TBL] [Abstract][Full Text] [Related]
5. Targeted Delivery of Cabazitaxel Using Cyclic Cell-Penetrating Peptide and Biomarkers of Extracellular Matrix for Prostate and Breast Cancer Therapy.
Park SE; El-Sayed NS; Shamloo K; Lohan S; Kumar S; Sajid MI; Tiwari RK
Bioconjug Chem; 2021 Aug; 32(8):1898-1914. PubMed ID: 34309357
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and biological evaluation of Doxorubicin-containing conjugate targeting PSMA.
Ivanenkov YA; Machulkin AE; Garanina AS; Skvortsov DA; Uspenskaya AA; Deyneka EV; Trofimenko AV; Beloglazkina EK; Zyk NV; Koteliansky VE; Bezrukov DS; Aladinskaya AV; Vorobyeva NS; Puchinina MM; Riabykh GK; Sofronova AA; Malyshev AS; Majouga AG
Bioorg Med Chem Lett; 2019 May; 29(10):1246-1255. PubMed ID: 30904185
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and therapeutic evaluation of an aptide-docetaxel conjugate targeting tumor-associated fibronectin.
Kim H; Lee Y; Lee IH; Kim S; Kim D; Saw PE; Lee J; Choi M; Kim YC; Jon S
J Control Release; 2014 Mar; 178():118-24. PubMed ID: 24462899
[TBL] [Abstract][Full Text] [Related]
8. Water-soluble polymers for targeted drug delivery to human squamous carcinoma of head and neck.
Nan A; Ghandehari H; Hebert C; Siavash H; Nikitakis N; Reynolds M; Sauk JJ
J Drug Target; 2005 Apr; 13(3):189-97. PubMed ID: 16036307
[TBL] [Abstract][Full Text] [Related]
9. Peptide-conjugated nanoparticles for targeted imaging and therapy of prostate cancer.
Yeh CY; Hsiao JK; Wang YP; Lan CH; Wu HC
Biomaterials; 2016 Aug; 99():1-15. PubMed ID: 27209258
[TBL] [Abstract][Full Text] [Related]
10. Extra-domain B of fibronectin as an alternative target for drug delivery and a cancer diagnostic and prognostic biomarker for malignant glioma.
Saw PE; Xu X; Kang BR; Lee J; Lee YS; Kim C; Kim H; Kang SH; Na YJ; Moon HJ; Kim JH; Park YK; Yoon W; Kim JH; Kwon TH; Choi C; Jon S; Chong K
Theranostics; 2021; 11(2):941-957. PubMed ID: 33391514
[TBL] [Abstract][Full Text] [Related]
11. Engineered breast tumor targeting peptide ligand modified liposomal doxorubicin and the effect of peptide density on anticancer activity.
Shahin M; Soudy R; Aliabadi HM; Kneteman N; Kaur K; Lavasanifar A
Biomaterials; 2013 May; 34(16):4089-4097. PubMed ID: 23465829
[TBL] [Abstract][Full Text] [Related]
12. CAR-T Therapy Targets Extra Domain B of Fibronectin Positive Solid Tumor Cells.
Tang J; Liu N; Zhu Y; Li Y; Zhao X
Immunol Invest; 2023 Nov; 52(8):985-996. PubMed ID: 37815216
[TBL] [Abstract][Full Text] [Related]
13. Transferrin Receptor Targeted Cellular Delivery of Doxorubicin Via a Reduction-Responsive Peptide-Drug Conjugate.
Li S; Zhao H; Mao X; Fan Y; Liang X; Wang R; Xiao L; Wang J; Liu Q; Zhao G
Pharm Res; 2019 Oct; 36(12):168. PubMed ID: 31654226
[TBL] [Abstract][Full Text] [Related]
14. The synthesis of a prodrug of doxorubicin designed to provide reduced systemic toxicity and greater target efficacy.
Garsky VM; Lumma PK; Feng DM; Wai J; Ramjit HG; Sardana MK; Oliff A; Jones RE; DeFeo-Jones D; Freidinger RM
J Med Chem; 2001 Nov; 44(24):4216-24. PubMed ID: 11708923
[TBL] [Abstract][Full Text] [Related]
15. Enhancing Accumulation and Penetration of HPMA Copolymer-Doxorubicin Conjugates in 2D and 3D Prostate Cancer Cells via iRGD Conjugation with an MMP-2 Cleavable Spacer.
Peng ZH; Kopeček J
J Am Chem Soc; 2015 Jun; 137(21):6726-9. PubMed ID: 25963409
[TBL] [Abstract][Full Text] [Related]
16. Preclinical Assessment of the Effectiveness of Magnetic Resonance Molecular Imaging of Extradomain-B Fibronectin for Detection and Characterization of Oral Cancer.
Hall RC; Ayat NR; Qiao PL; Vaidya AM; Ma D; Aminoshariae A; Stojanov I; Lu ZR
Mol Imaging Biol; 2020 Dec; 22(6):1532-1542. PubMed ID: 32789648
[TBL] [Abstract][Full Text] [Related]
17. Comparative studies of polyethylenimine-doxorubicin conjugates with pH-sensitive and pH-insensitive linkers.
Dong DW; Tong SW; Qi XR
J Biomed Mater Res A; 2013 May; 101(5):1336-44. PubMed ID: 23065848
[TBL] [Abstract][Full Text] [Related]
18. Synthesis, in vitro stability, and antiproliferative effect of d-cysteine modified GnRH-doxorubicin conjugates.
Li S; Zhao H; Chang X; Wang J; Zhao E; Yin Z; Mao X; Deng S; Hao T; Wang H; Yang Y
J Pept Sci; 2019 Jan; 25(1):e3135. PubMed ID: 30467919
[TBL] [Abstract][Full Text] [Related]
19. The conjugates of forky peptides and nonsteroidal anti-inflammatory drugs (NSAID) self-assemble into supramolecular hydrogels for prostate cancer-specific drug delivery.
Tao M; He S; Liu J; Li H; Mei L; Wu C; Xu K; Zhong W
J Mater Chem B; 2019 Jan; 7(3):469-476. PubMed ID: 32254734
[TBL] [Abstract][Full Text] [Related]
20. Polymeric nanomedicine for tumor-targeted combination therapy to elicit synergistic genotoxicity against prostate cancer.
Yang Q; Yang Y; Li L; Sun W; Zhu X; Huang Y
ACS Appl Mater Interfaces; 2015 Apr; 7(12):6661-73. PubMed ID: 25775367
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
